Tritz, Z. P., Ayasoufi, K., Wolf, D. M., Owens, C. A., Malo, C. S., Himes, B. T., … Johnson, A. J. (2023). Supplementary Figure 1 from Anti–PD-1 and Extended Half-life IL2 Synergize for Treatment of Murine Glioblastoma Independent of Host MHC Class I Expression. https://doi.org/10.1158/2326-6066.22713695

Tritz, Zachariah P., Katayoun Ayasoufi, Delaney M. Wolf, Carley A. Owens, Courtney S. Malo, Benjamin T. Himes, Cori E. Fain, et al. “Supplementary Figure 1 from Anti–PD-1 and Extended Half-life IL2 Synergize for Treatment of Murine Glioblastoma Independent of Host MHC Class I Expression,” April 27, 2023. https://doi.org/10.1158/2326-6066.22713695.

Tritz ZP, Ayasoufi K, Wolf DM, Owens CA, Malo CS, Himes BT, et al. Supplementary Figure 1 from Anti–PD-1 and Extended Half-life IL2 Synergize for Treatment of Murine Glioblastoma Independent of Host MHC Class I Expression. 2023.

Tritz, Zachariah P., et al. Supplementary Figure 1 from Anti–PD-1 and Extended Half-life IL2 Synergize for Treatment of Murine Glioblastoma Independent of Host MHC Class I Expression. 27 Apr. 2023. Crossref, doi:10.1158/2326-6066.22713695.

Tritz ZP, Ayasoufi K, Wolf DM, Owens CA, Malo CS, Himes BT, Fain CE, Goddery EN, Yokanovich LT, Jin F, Hansen MJ, Parney IF, Wang C, Moynihan KD, Irvine DJ, Wittrup KD, Diaz Marcano RM, Vile RG, Johnson AJ. Supplementary Figure 1 from Anti–PD-1 and Extended Half-life IL2 Synergize for Treatment of Murine Glioblastoma Independent of Host MHC Class I Expression. 2023.